業績(2025まで) / 最近 /preprint/submit/revision
2026 (1月23日時点で合計4報)
- 443. Mizuno T, Harada K, Ichimata M, Katayama R, Kato Y, Shiga T, Tsukui T, Toyoda H, Fukazawa E, Matsuyama F, Igase M, Kobayashi T.
Afucosylated anti-canine CD20 antibody combined with CHOP therapy in canine B-cell lymphoma
J Vet Intern Med, 40(1), aalaf039, https://doi.org/10.1093/jvimsj/aalaf039, 2026 (PDF)
- 442. Yamamoto H, Suzuki H, Tanaka T, Satofuka H, Kaneko MK, Kato Y.
Development of a novel anti-mouse CCR7 monoclonal antibody C7Mab-2 by immunization of the extracellular loop domain
Microbes & Immunity, 3(1), 172–180; https://doi.org/10.36922/MI025130028, 2026 (PDF; preprint)
- 441. Hitomi N, Hoshi S, Kaneko MK, Kato R, Iwasaki K, Takagi J, Kato Y, Harada-Hikita A, Arimori T.
Functional and structural characterisation of a novel anti-His-tag antibody, HisMab-1
J Mol Biol, 438(2), 169574, doi: 10.1016/j.jmb.2025.169574, 2026 (PDF)
- 440. Ubukata R, Suzuki H, Kaneko MK, Kato Y.
Development of novel anti-CDH1/E-cadherin monoclonal antibodies for flow cytometry, western blotting, and immunohistochemistry
BBREP, 45, 102401, https://www.sciencedirect.com/science/article/pii/S2405580825004881, 2026 (PDF; preprint)
online (1月23日時点で合計7報)
- Sudo H, Tsuji AB, Sugyo A, Kaneko MK, Kato Y, Higashi T.
Intrathoracic 90Y-NZ-16 therapy improves efficacy and reduces toxicity in pleural mesothelioma mice
Nucl Med Commun., doi: 10.1097/MNM.0000000000002112, 2026
- Yoshida A, Abe S, Izumi T, Itakura S, Yamada K, Wada T, Yamamoto T, Sato C, Mitsuhashi A, Ogino H, Sato S, Shinohara T, Hanibuchi M, Kaneko MK, Kato Y, Nishioka Y.
Cancer-specific anti-human podoplanin antibody chLpMab-2f exerts antitumor effects against pleural mesothelioma
Cancer Sci, https://doi.org/10.1111/cas.70325, 2026 (PDF)
- Li G, Suzuki H, Kaneko MK, Kato Y.
Establishment of novel anti-EphB3 monoclonal antibodies for multiple applications
Monoclon Antib Immunodiagn Immunother, https://doi.org/10.1177/216794362514083, 2026 (PDF; preprint)
- Li G, Tanaka T, Kaneko MK, Suzuki H, Kato Y.
Ea5Mab-7, a novel anti-EphA5 monoclonal antibody for flow cytometry and immunohistochemistry.
Microbes & Immunity, 025300066, https://doi.org/10.36922/MI025300066, 2026 (PDF; preprint)
- Fujisawa S, Ubukata R, Suzuki H, Tanaka T, Nomura A, Shinoda K, Nakamura T, Satofuka H, Li G, Kaneko MK, Kato Y.
Development of novel anti-rhinoceros podoplanin monoclonal antibodies for flow cytometry, western blot, and immunohistochemistry
Microbes & Immunity, 2026 (PDF; preprint)
- Tanaka T, Sakata T, Fujisawa S, Yamamoto H, Kaneko Y, Kaneko MK, Suzuki H, Kato Y.
Establishment of a novel anti-mouse CD73 monoclonal antibody C73Mab-9 by CBIS method
Microbes & Immunity, 025220048, https://doi.org/10.36922/MI025220048, 2026 (PDF; preprint)
- Fujisawa S, Yamamoto H, Tanaka T, Kaneko MK, Suzuki H, Kato Y.
Development and characterization of Ea7Mab-10: a novel monoclonal antibody targeting EphA7
Microbes & Immunity, 025220049, https://doi.org/10.36922/MI0252200492025, 2026 (PDF; preprint)
proof (1月7日時点で合計1報)
- Taruta H, Tanaka T, Kaneko MK, Suzuki H, Kato Y.
Cx2Mab-5: a Novel anti-mouse CXCR2 monoclonal antibody developed by N-terminus peptide Immunization for multiple applications
MAB-2025-0017, 2025 (PDF; preprint)
accept (1月23日時点で合計1報)
- Yamamoto H, Suzuki H, Tanaka T, Kaneko MK, Kato Y.
Development of an anti-Glypican-1 monoclonal antibody G1Mab-28 for flow cytometry, western blotting, and immunohistochemistry
Microbes & Immunity, 2026 (PDF; preprint)
業績(2025まで) / 最近 / preprint/submit/revision
業績
業績検索
